1. Oral Therapies in MS

3. Program Goals

4. Patient Case

5. Switching to an Oral DMT

6. Therapeutic Switching

7. Safety Concerns With Oral DMTs

8. Fingolimod Mechanism of Action

9. Fingolimod Routine Monitoring

10. Fingolimod Safety

11. Fingolimod Efficacy

12. Switching to Fingolimod

13. Teriflunomide Mechanism of Action

14. Teriflunomide Efficacy

15. Teriflunomide and NEDA

16. SIENA Analysis: The Effect of Teriflunomide on Brain Volume Loss

17. Comparing Oral Therapies

18. Dimethyl Fumarate Mechanism of Action

19. Dimethyl Fumarate Adverse Events

20. Dimethyl Fumarate Adherence

21. Dimethyl Fumarate Efficacy

22. Safety and Tolerability

23. PML

24. Tolerability

25. Therapeutic Sequencing

26. Case Continuation

27. Oral Therapies in the United States and Europe

28. Abbreviations

29. Abbreviations (cont)